ATNM
AMEX · Biotechnology
Actinium Pharmaceuticals Inc
$1.26
-0.02 (-1.56%)
Open$1.28
Previous Close$1.28
Day High$1.33
Day Low$1.25
52W High$1.95
52W Low$0.95
Volume—
Avg Volume130.6K
Market Cap39.22M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,765.9% upside
Current
$1.26
$1.26
Target
$36.11
$36.11
$23.47
$36.11 avg
$39.96
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 90.3K | 203.4K | 4.99M |
| Net Income | -33,812,156 | -68,584,494 | -1,193,914 |
| Profit Margin | -37,652.2% | -35,769.6% | -23.9% |
| EBITDA | -35,994,088 | -77,066,449 | -1,575,968 |
| Free Cash Flow | — | — | -691,464 |
| Rev Growth | -55.6% | -55.6% | +20.9% |
| Debt/Equity | 0.00 | 0.00 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |